hotspot -WSS

hotspot

author：entertainment 2025-08-28 08:40:49 - browse：53

Adam's take main illustration — Molly Ferguson/STAT

MoonLake Immunotherapeutics, a Swiss biotech, was buried Monday under an avalanche of its own data spin.

It’s been awhile since I encountered a management team that speaks so arrogantly about the supposed supremacy of its own drug, but then fails to back up the talk with real data. MoonLake claimed its experimental antibody called sonelokimab delivered “landmark” results in a mid-stage study of psoriatic arthritis.

Landmark? That’s a strange way of describing the results of a clinical trial that showed sonelokimab topping a placebo — an easy hurdle — but failing to separate from an active treatment comparator, the generic drug adalimumab (known better as Humira).

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Physician subsidies by hospitals soar in wake of No Surprises Act

WSS

Celiac disease study examines precisely how gluten triggers injury

Mike Pence clashes with Tucker Carlson in Iowa

Michigan AG announces felony charges against 'fake electors' in 2020 election plot

Georgia court denies Trump's request to quash DA's 2020 election probe

The new HIV moral panic

Traditional Chinese medicine benefits explored in new JAMA study

entertainment

hotspot

hotspot

Activists slam private health insurers over coverage restrictions

Testing for cancer recurrence creates a new limbo for patients

Medical leaders decry Supreme Court decision on affirmative action

Paying for Covid pills will soon shift to insurers

After affirmative action ruling, medical educators look to 'holistic review'

Everything to know for the next Powerball drawing as jackpot hits $1 billion

Hollywood unions extend contract negotiations for actors

Eli Lilly to pay $200M for Beam’s stake in gene

Cancer drug shortages should be causing more outrage

Blood tests recalled over risk of missed heart attack diagnosis

hotspot

Blood tests recalled over risk of missed heart attack diagnosis

Readout Newsletter: XBI biotech index, Akero Therapeutics

Care demand spikes challenge UnitedHealth’s provider arm

Physician subsidies by hospitals soar in wake of No Surprises Act

Why police arrested suspected Gilgo Beach killer away from his house

Eli Lilly to pay $200M for Beam’s stake in gene

hotspot

Wikipedia

leisure time

explore